March 2018March 2018
New Indications
Abilify Maintena (aripiprazole) is now indicated as monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar I disorder in adults.
Keytruda (pembrolizumab (rch)) is now indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have received platinum containing chemotherapy, and in patients not eligible for cisplatin containing therapy.
Orencia (abatacept (rch)) is now indicated for the treatment of active psoriatic arthritis in adults when the response to previous disease modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Orencia can be used with or without non-biologic DMARDs.
Stivarga (regorafenib) is now indicated for the treatment of hepatocellular carcinoma in patients who have been previously treated with sorafenib.
Victoza (liraglutide (rys)) is now indicated as an adjunct to diet and exercise for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control as monotherapy when metformin is contraindicated or is not tolerated. When indicated to improve glycaemic control, Victoza is now also indicated to reduce the risk of cardiovascular events in patients at high cardiovascular risk, as an adjunct to standard of care therapy.
Vyvanse (lisdexamfetamine dimesilate) is now indicated for the treatment of moderate to severe binge eating disorder in adults when non-pharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist, and is indicated as part of a total treatment program that optimally includes other measures (nutritional, psychological and medical) for patients with this disorder.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au